Literature DB >> 34304793

Psychopharmacologic Therapies for Irritable Bowel Syndrome.

Hans Törnblom1, Douglas A Drossman2.   

Abstract

Psychopharmacologic therapies are beneficial in reducing symptoms when treating irritable bowel syndrome (IBS) and other disorders of gut-brain interaction (DGBI). Noradrenaline, serotonin, and dopamine are neurotransmitters of key importance in psychopharmacology and pain-reduction mechanisms. The first-line (tricyclic antidepressants, serotonin noradrenaline reuptake inhibitors, selective serotonin reuptake inhibitors) and second-line (atypical antipsychotics, delta-ligand agents, low-dose naltrexone) neuromodulator treatment options are recommended when IBS-associated abdominal pain is of moderate or severe intensity and is persistent. To understand the implementation strategy, the multidimensional clinical profile as a template is used for presenting 3 case scenarios involving painful IBS and DGBI of varying complexity.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antidepressants; Disorders of gut brain interaction; Irritable bowel syndrome; Multidimensional clinical profile; Neuromodulator; Treatment

Year:  2021        PMID: 34304793     DOI: 10.1016/j.gtc.2021.04.005

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  1 in total

1.  Insights on Disorders of Gut-Brain Interaction.

Authors:  Gregory S Sayuk
Journal:  Gastroenterol Hepatol (N Y)       Date:  2021-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.